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OBJECTIVES: 3-Aminobenzanthrone (3-ABA) is the main human metabolite of 20 
carcinogenic environmental pollutant 3-nitrobenzanthrone (3-NBA). Understanding 21 
which cytochrome P450 (CYP) enzymes are involved in metabolism of this toxicant is 22 
important in the assessment of individual susceptibility. Characterization of 3-ABA 23 
metabolites formed by rat hepatic microsomes containing cytochromes P450 (CYPs) 24 
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and identification of the major rat and human CYPs participating in this process are 25 
aims of this study.  26 
METHODS: HPLC with UV detection was employed for the separation and 27 
characterization of 3-ABA metabolites. Inducers and inhibitors of CYPs and rat and 28 
human recombinant CYPs were used to characterize the enzymes participating in 3-29 
ABA oxidation. 30 
RESULTS: Selective CYP inhibitors and hepatic microsomes of rats pre-treated with 31 
specific CYP inducers were used to characterize rat liver CYPs metabolizing 3-ABA 32 
(measured as consumption of 3-ABA). Kinetics of these reactions catalyzed by rat 33 
hepatic microsomes was also evaluated. Based on these studies, we attribute most 34 
of 3-ABA metabolism in rat liver to CYP1A and 3A. Among recombinant rat and 35 
human CYP enzymes tested in this study, rat CYP3A2 and human CYP3A4/5, 36 
followed by CYP1A1 of both organisms were the most effective enzymes converting 37 
3-ABA. Rat hepatic CYP enzymes oxidize 3-ABA up to three metabolites. Two of 38 
them were identified to be the products formed by oxidation of 3-ABA on its amino 39 
group back to the parent compound from which 3-ABA is generated in organisms, 3-40 
NBA. Namely, N-hydroxylation metabolite, N-hydroxy-3-ABA and 3-NBA were 41 
identified to be these 3-ABA oxidation products. These metabolites are formed by 42 
CYPs of a 1A subfamily. Another 3-ABA metabolite, whose structure remains to be 43 
characterized, is generated not only by CYP1A but also by other CYP enzymes, 44 
predominantly by CYPs of a 3A subfamily.   45 
CONCLUSIONS: The results found in this study, the first report on the metabolism of 46 
3-ABA by human and rat CYPs, clearly demonstrate that CYPs of 3A and 1A 47 
subfamilies are the major enzymes metabolizing 3-ABA.  48 
 49 
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ABBREVIATIONS & UNITS 53 
3-ABA – 3-aminobenzanthrone 54 
α-NF - α-naphthoflavone 55 
β-NF - β-naphthoflavone 56 
cDNA - complementary DNA 57 
CYP - cytochrome P450 58 
DDTC - diethyldithiocarbamic acid 59 
HPLC - high performance liquid chromatography 60 
Km - Michaelis constant  61 
MS - microsomes 62 
N-hydroxy-3-ABA - N-hydroxy-3- aminobenzanthrone 63 
NADPH - nicotinamidadeninedinucleotide phosphate (reduced) 64 
3-NBA – 3-nitrobenzatntrone 65 
PB – phenobarbital 66 
RP – reverse phase 67 
r.t. – retention time 68 
UV – ultraviolet 69 
VIS - visible 70 
Vmax - maximum reaction rate  71 
 72 
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INTRODUCTION 73 
The nitroaromatic compound 3-nitrobenzanthrone (3-nitro-7H-74 
benz[de]anthracen-7-one, 3-NBA, Fig. 1) is one of the most potent mutagens and a 75 
suspected human carcinogen that is found in diesel exhaust and ambient air pollution 76 
(Arlt, 2005, Hansen et al., 2007). We found that 3-NBA is activated to N-hydroxy-3- 77 
aminobenzanthrone (N-hydroxy-3-ABA) by cytosolic and microsomal reductases by 78 
simple nitroreduction (Arlt 2005, Arlt et al., 2002, 2003a,b,c, 2005, Stiborova et al., 79 
2006a, 2008, 2009, Svobodova et al. 2007) (Figure 1).  80 
Recently 3-NBA has received much attention due to its extremely high 81 
mutagenic potency in the Ames Salmonella assay (Enya et al., 1997; Seidel et al., 82 
2002; Arlt, 2005). 3-NBA is carcinogenic in rats, causing lung tumours after 83 
intratracheal instillation, and it is also a suspected human carcinogen (Seidel et al., 84 
2002; Arlt, 2005; Nagy et al., 2005).  85 
The uptake of 3-NBA in humans has been demonstrated by the detection of its 86 
metabolite 3-aminobenzanthrone (3-ABA, Figure 1) in urine samples of salt mine 87 
workers occupationally exposed to diesel emissions (Seidel et al., 2002). 3-ABA was 88 
also the main metabolite of 3-NBA formed in human fetal bronchial cells and rat lung 89 
alveolar type II cells (Borlak et al., 2000).  90 
3-ABA was also evaluated to be suitable for coloration of microporous 91 
polyethylene films, which are widely used for practical purposes such as separation 92 
of liquid mixtures, in particular, as separation membranes in chemical batteries 93 
(Grabchev et al., 2002), or an advantageous fluorescent phospholipid membrane 94 
label in the form of its N-palmitoyl derivative (Sykora et al., 2002). This suggests 95 
industrial and/or laboratory utilization of this 3-NBA metabolite, leading to a putative 96 
exposure of people. This is a matter of concern, because we have demonstrated the 97 
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genotoxicity of both 3-NBA and 3-ABA by the detection of specific DNA adducts 98 
formed in vitro and in vivo (Arlt et al., 2001; 2002; 2003a; b; c; 2004a; c; 2005; 99 
2006b; Bieler et al., 1999; 2005; 2007; Stiborova et al., 2006a; 2008, 2009). Previous 100 
work indicated that N-hydroxy-3-ABA appears to be the critical intermediate in 3-101 
NBA/ABA-derived DNA adduct formation (Figure 1), which can be further activated 102 
by N,O-acetyltransferases (NATs) and sulfotransferases (SULTs) (Arlt et al., 2002, 103 
2003a, b,  2005). The predominant DNA adducts formed from 3-NBA and 3-ABA are 104 
2-(2’-deoxyguanosin-N2-yl)-3-aminobenzanthrone (dG-N2-ABA) and N-(2’-105 
deoxyguanosin-8-yl)-3-aminobenzanthrone (dG-C8-N-ABA) and these are most 106 
probably responsible for the induction of GC to TA  transversion mutations induced 107 
by these toxicants (Arlt et al., 2004a; Arlt et al., 2006b; Bieler et al., 2007).  108 
Understanding which enzymes are involved in the metabolism (activation 109 
and/or detoxication) of 3-ABA is important in the assessment of susceptibility to this 110 
3-NBA metabolite. Recently, we have found that cytochromes P450 (CYP) 1A1 and 111 
1A2 are essential for 3-ABA oxidative activation in human and rat liver, lung and 112 
kidney to reactive species, N-hydroxy-3-ABA, forming the same DNA adducts that 113 
are formed in vitro and in vivo in rodents by 3-ABA or 3-NBA (Arlt et al. 2003a, b, c, 114 
2004b, 2005, 2006a, Stiborova et al. 2006a; 2008, 2009) (Figure 1).  115 
In contrast to the enzymes activating 3-ABA to species binding to DNA, those 116 
participating in 3-ABA oxidation to other potential metabolites have not been 117 
extensively studied so far. Therefore, here we investigated the oxidative metabolism 118 
of 3-ABA in vitro, in order to characterize the 3-ABA metabolites and to identify CYPs 119 
responsible for their formation. Hepatic microsomal systems and recombinant CYP 120 
enzymes of rat, the organism found previously to be a suitable model mimicking 121 
activation metabolism of 3-ABA in human (Arlt et al., 2004b) were used for such a 122 
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study. In addition, rat and human recombinant CYP enzymes were utilized to 123 
characterize their participation in 3-ABA oxidation. 124 
 125 
MATERIAL AND METHODS 126 
Synthesis of 3-ABA and N-hydroxy-3-ABA. 3-ABA and N-hydroxy-3-ABA were 127 
synthesized as described by Arlt et al. (2003a) and their authenticity was confirmed 128 
by UV spectroscopy, electrospray mass spectra and high field proton NMR 129 
spectroscopy. 130 
Chemicals and enzymes. Microsomes from rat livers were isolated and characterized 131 
for CYP activities as described (Arlt et al., 2004b, Stiborova et al., 2006a,b). 132 
Supersomes, microsomes isolated from insect cells transfected with Baculovirus 133 
constructs containing cDNA of one of the following rat CYPs: CYP1A1, 1A2, 2A1, 134 
2A2, 2B1, 2C6, 2C11, 2C12, 2C13, 2D1, 2D2, 2E1, 3A1, 3A2 with cytochrome b5 and 135 
expressing NADPH:CYP reductase and one of the following human CYPs: CYP1A1, 136 
1A2, 2A6, 2B6, 2C8 (with and without cytcohrome b5), 2C19 (with and without 137 
cytochrome b5),, 2D6, 2E1, 3A4 and 3A5 (with and without cytcohrome b5), and 138 
expressing NADPH:CYP reductase were obtained from Gentest Corp. (USA). 139 
NADPH, phenacetine, dimethylsulfoxide (DMSO) were obtained from Sigma 140 
Chemical Co (St Louis, MO, USA), ethylacetate, methanol for high performance 141 
liquid chromatography (HPLC) super gradient, methanol were obtained from 142 
Lachema, (Brno, Czech Republic).  143 
Animal experiments and preparation of microsomes. The study was conducted in 144 
accordance with the Regulations for the Care and Use of Laboratory Animals 145 
(311/1997, Ministry of Agriculture, Czech Republic), which complies with the 146 
Declaration of Helsinki. Microsomes from livers of ten male untreated Wistar rats and 147 
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those from livers of ten male rats pre-treated with β-naphtoflavone (β-NF) and 148 
phenobarbital (PB) were prepared by the procedure described previously (Arlt et al., 149 
2004b, Stiborova et al., 2002b, 2006b,. Krizkova et al., 2008, Sistkova et al., 2008). 150 
Protein concentrations in the microsomal fractions were assessed using the 151 
bicinchoninic acid protein assay with the bovine serum albumin as a standard 152 
(Weichelman et al., 1988). The concentration of CYP was estimated according to 153 
Omura and Sato (Omura and Sato, 1964) based on absorption of the complex of 154 
reduced CYP with carbon monoxide. Untreated rat liver microsomes contained 0.6 155 
nmol CYP/mg protein. Hepatic microsomes of rats treated with β-NF and PB 156 
contained 1.3 and 1.5 nmol CYP/mg proteins, respectively.  157 
Incubations. Unless stated otherwise, incubation mixtures used for studying 3-ABA 158 
metabolism by rat hepatic microsomes were prepared as described previously by 159 
Mizerovska et al. (2008). Briefly, incubation mixtures, containing final volume of 500 160 
µl, consisted of 100 mM potassium phosphate buffer (pH 7.4), 10 mM NADPH, 0.5 161 
mg of microsomal protein and 5 - 50 µM 3-ABA (dissolved in DMSO). The reaction 162 
was initiated by adding 3-ABA. Incubations with rat microsomes were carried out at 163 
37 °C for 5 minutes. Control incubations were carried out either without the 164 
enzymatic system (microsomes) or without NADPH. Incubation mixtures used for 165 
studying 3-ABA metabolism by rat and human recombinant CYP enzymes  contained 166 
final volume of 250 µl, consisting of 100 mM potassium phosphate buffer (pH 7.4), 10 167 
mM NADPH, 1 µM CYP in SupersomesTM and 20 µM 3-ABA (dissolved in DMSO). 168 
All incubations were carried out at 37 °C for 20 min. In the case of investigation of the 169 
time dependence of 3-ABA oxidation, reaction mixtures were incubated at 37°C for 0 170 
- 120 minutes. Control incubations were carried out either without the CYP enzymes 171 
(SupersomesTM) or without NADPH. Then, 2.5 or 5 µl of 1 mM phenacetine in 172 
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methanol was added as an internal standard, and 3-ABA and its metabolites were 173 
extracted twice with ethyl acetate (2 x 1.5 ml). The extracts were evaporated to 174 
dryness; residues dissolved in 30 µl of methanol and subjected to reverse-phase 175 
(RP)-HPLC to evaluate the amounts of residual 3-ABA and its metabolites. The 3-176 
ABA metabolites were separated from 3-ABA by HPLC with UV detection and 177 
characterized by mass spectrometry and co-chromatography with synthetic 178 
standards. The following chemicals were used in the inhibition studies of the 3-ABA 179 
oxidation by hepatic microsomes: α-naphthoflavone (α-NF), which inhibits CYP1A1 180 
and 1A2; furafylline, which inhibits CYP1A2, diamantane, which inhibits CYP2B 181 
(Stiborova et al., 2002a); sulphafenazole, which inhibits CYP2C; 182 
diethyldithiocarbamic acid (DDTC), which inhibits CYP2E1 and ketoconazole, which 183 
inhibits CYP3A (Rendic & DiCarlo, 1997). Inhibitors were dissolved in ethanol, except 184 
of α-NF that was dissolved in a mixture of methanol:ethylacetate (3:2, v/v) and DDTC 185 
that was dissolved in distilled in water, to yield final concentrations of 1-1000 µM in 186 
the incubation mixtures.  187 
HPLC. HPLC was performed with a reversed phase column (Nucleosil 100-5 C18, 188 
Macherey-Nagel, Duren, Germany, 25 cm x 4.6 mm, 5 mm) proceeded by a C-18 189 
guard column, using isocratic elution conditions of 70% methanol in distilled water 190 
with a flow rate of 0.6 ml/min. HPLC was carried out with a Dionex HPLC pump P580 191 
with UV/VIS UVD 170S/340S spectrophotometer detector set at 254 nm, and peaks 192 
were integrated with a CHROMELEONTM 6.01 integrator. 3-ABA, N-hydroxy-3-ABA, 193 
and 3-NBA were eluted with retention times (r.t.) of 8.2, 6.5 and 25 minutes, 194 
respectively (Figure 2)   195 
 196 
RESULTS 197 
 9
When 3-ABA was incubated with rat hepatic microsomes in the presence of 198 
NADPH up to three product peaks were separated by HPLC (see Figure 2 for hepatic 199 
microsomes of rats treated with β-NF). Using co-chromatography with synthetic 200 
standards, two of them were identified to be the products formed by oxidation of 3-201 
ABA on its amino group back to the parent compound from which 3-ABA is 202 
generated in organisms, 3-NBA. Namely, N-hydroxylation metabolite, N-hydroxy-3-203 
ABA and 3-NBA were identified to be these 3-ABA oxidation products. This finding 204 
indicates that 3-ABA might, in some cases, be oxidized through N-hydroxy-3-ABA 205 
back to its oxidative counterpart, 3-NBA (Figure 1). A structure of another metabolite 206 
eluted with the retention time (r.t.) of 18 min, M18 (Figure 2A) remains to be 207 
characterized.  208 
We have used hepatic microsomes of rats treated with CYP inducers (an inducer 209 
of CYP1A1/2, β-NF and an inducer CYP2B1/2, PB), as well as inhibitors of individual 210 
CYPs, to evaluate the role of rat hepatic CYPs in 3-ABA metabolism (Mizerovska et 211 
al., 2008). Here, the same microsomal systems and hepatic microsomes of control 212 
(untreated) rats were utilized to determine the kinetics of 3-ABA metabolism. If 3-ABA 213 
was incubated with these microsomes more than 30 minutes, different patterns of 3-214 
ABA metabolic products were found in individual microsomes. Whereas hepatic 215 
microsomes rich in CYP1A1/2 (β-NF-microsomes) generated the final oxidation 216 
metabolite of 3-ABA, 3-NBA (Figure 1), this metabolite (3-NBA) was not formed by 217 
the other microsomes tested in the study (Figure 3). The metabolite with unknown 218 
structure, M18, was the only one formed from 3-ABA by these enzymatic systems 219 
(Figure 3). It should be mentioned that in some cases the control incubations without 220 
presence of microsomes contained traces of 3-ABA metabolites, 3-NBA and a 221 
metabolite M18 (see Figure 3A showing this case), which might probably be formed 222 
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by autooxidation. N-hydroxy-3-ABA was another metabolite generated by 223 
microsomes rich in CYP1A1/2 (Figure 2A), but this metabolite was not quantified in 224 
this study, namely, because this reactive compound is easily decomposed and forms 225 
nitrenium and/or carbenium ion (Figure 1), being scavenged by proteins (at least 226 
partially) present in the incubation mixtures. When shorter incubation times were 227 
used in the experiments, formation of all 3-ABA oxidation products detected in the 228 
above experiments was low, being hardly to be quantified. Hence, because the 229 
incubation times during them the conversion of 3-ABA is linear (that are shorter than 230 
30 minutes, see below) are needed to study kinetics of 3-ABA metabolism by 231 
microsomes, the consumption of 3-ABA, detected during such short incubation times, 232 
has been used to evaluate initial velocities of the enzymatic reactions. Conversion of 233 
3-ABA by all three hepatic microsomes (measured by consumption of 3-ABA) was 234 
linear up to 5 minutes of incubation (data not shown). This time interval was, 235 
therefore, used to evaluate kinetics of 3-ABA oxidation. 236 
A classical Michaelis-Menten kinetics was found for 3-ABA metabolism by 237 
hepatic microsomes of rats treated with β-NF and PB; double reciprocal plots of initial 238 
velocities versus concentrations of 3-ABA were linear (Figure 4A,B). The values of 239 
Michaelis constant (Km) and maximum reaction velocity (Vmax) determined from this 240 
kinetics are shown in Table 1. The values of Km and Vmax for 3-ABA metabolism by 241 
PB-microsomes were more than 1.2-fold higher than those by hepatic microsomes of 242 
rats treated with β-NF. 243 
In contrast to the kinetics found with rat hepatic β-NF- and PB-microsomes, 244 
double reciprocal plots of kinetics of 3-ABA oxidation by hepatic microsomes of 245 
control (untreated) rats were not linear (Figure 4C), giving two Km values for 3-ABA 246 
(Table 1). These findings indicate that more than one of the CYP enzymes present in 247 
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these microsomes are responsible for 3-ABA metabolism. Because one of the Km 248 
values is close to the value of Km found with microsomes rich in CYP1A1/2 (β-NF-249 
microsomes), the enzyme of a CYP1A subfamily might be important for 3-ABA 250 
conversion in hepatic microsomes of control rats. Indeed, inhibitors of CYPs of a 1A 251 
subfamily (α-NF for CYP1A1/2 and furafylline for CYP1A2) are strong inhibitors of 3-252 
ABA metabolism (Table 2). Results of experiments utilizing CYP inhibitors also 253 
suggest that CYP enzymes of a 3A subfamily might participate in 3-ABA metabolism 254 
in rat hepatic microsomes; a selective CYP3A inhibitor, ketoconazole, was highly 255 
effective in inhibiting 3-ABA conversion, with the IC50 value of 3.5 µM (Table 2).   256 
To further characterize the role of individual rat CYPs in 3-ABA metabolism and 257 
to compare their efficiencies with those of human CYP enzymes, microsomes of 258 
Baculovirus transfected insect cells (SupersomesTM) containing recombinantly 259 
expressed rat and human CYPs and NADPH:CYP reductase were utilized in an 260 
additional part of this study. 261 
First, a time-dependence of 3-ABA conversion catalyzed by rat recombinant 262 
CYP1A1, 3A1 and 3A2, the enzymes found in the above experiments to be important 263 
in 3-ABA metabolism in rat liver microsomes, and that of their human orthologous 264 
CYPs (CYP1A1 and 3A4) was investigated. Whereas 3-ABA conversion catalyzed by 265 
human and rat CYP1A1, rat CYP3A1 and human CYP3A4 is linear up to 20 minutes 266 
of incubations, that by rat CYP3A2 is linear even up to 40 minutes of incubation (data 267 
not shown). Because of linearity of 3-ABA conversion till 20 minutes, this time interval 268 
was used in experiments evaluating the efficiency of individual human and rat CYPs 269 
to metabolize 3-ABA.   270 
All rat and human recombinant CYP tested in this study were effective to 271 
metabolize 3-ABA (Figure 5). Among them CYPs of a 3A subfamily (CYP3A2 and 272 
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3A4/5) followed by CYP1A1 were the most efficient enzymes of both organisms 273 
metabolizing 3-ABA. In addition, rat CYP2C11 and human CYP2A6, 2C19 and 2D6 274 
were also effective in this reaction (Figure 5)       275 
 276 
DISCUSSION 277 
3-ABA, the human metabolite of the ubiquitous environmental pollutant 3-NBA, 278 
was detected in the urine of smoking and nonsmoking salt mining workers 279 
occupationally exposed to diesel emissions at similar concentration (1-143 ng/24 h 280 
urine) to 1-aminopyrene (2-200 ng/24 h urine), the corresponding amine of the most 281 
abundant nitro-polycyclic aromatic hydrocarbons detected in diesel exhaust matter 282 
(Seidel et al. 2002). Comparison between experimental animals and human CYP 283 
enzymes is essential for the extrapolation of animal toxicity data to assess human 284 
health risk. Therefore, here we compared the ability of rat and human CYP enzymes 285 
to metabolize 3-ABA.  286 
The results found in the presented study have increased our knowledge on the 287 
potential of human and rat CYP enzymes to metabolize 3-ABA and on the kinetics of 288 
such reactions. Two experimental approaches were utilized in this study. For the first, 289 
we used hepatic microsomal systems of rat found to be a suitable experimental 290 
model (based on the fact that the same enzymes activate 3-ABA in human and rat 291 
livers to form DNA adducts) (Arlt et al. 2004b; 2006c, Stiborova et al. 2006a). 292 
Therefore, the results should provide some indications of what might occurs with 3-293 
ABA in livers of human. The second approach employed rat and human recombinant 294 
CYP enzymes, which should mimic the enzymatic activity of actual CYP enzymes of 295 
both organisms.  296 
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Recently, were have found that rat and human hepatic CYP1A1 and 1A2, 297 
followed by human CYP2A6, are predominantly responsible for metabolic activation 298 
of 3-ABA to form DNA adducts. The extrahepatic enzymes CYP1B1 and 2B6 were 299 
also effective to activate 3-ABA, but to a much lower extent (Arlt et al. 2004b). On the 300 
contrary, none of the other CYP enzymes such as CYP2C9, 2D6, 2E1 and 3A4 301 
tested in this former study activated 3-ABA to species generating DNA adducts (Arlt 302 
et al. 2004b). This finding corresponds to results found in the present study. We have 303 
found that CYP1A enzymes are effective in oxidation of 3-ABA to the final oxidative 304 
metabolite of this substance, 3-NBA. Namely, to the metabolite that is formed 305 
through the formation of N-hydroxy-3-ABA. This reactive intermediate (N-hydroxy-3-306 
ABA) found in this study to be formed by CYP1A enzymes, is also decomposed to 307 
the ultimate carcinogenic species of 3-ABA, nitrenium and/or carbenium ions, forming 308 
the 3-ABA-derived DNA adducts (Figure 1). Hence, this metabolic activation pathway 309 
seems to be mediated mainly by the CYP1A enzymes. On the contrary, 3-ABA 310 
oxidation to further product(s) such as metabolite M18, which is supposed to be a 311 
detoxification metabolite (Mizerovska et al. 2008), is catalyzed not only by CYP1A, 312 
but also by other rat CYP enzymes. As follows from the studies on kinetics of 3-ABA 313 
metabolism (presented study) as well as from the effects of selective inhibitors of 314 
individual CYPs (Mizerovska et al. 2008 and presented study), beside CYP1A, the 315 
CYP enzymes of 3A and 2C subfamilies might be very effective in such 3-ABA 316 
metabolism in rat livers. Using rat recombinant CYPs, this suggestion was confirmed; 317 
rat CYP3A2 followed by CYP1A1, 2C11 and 3A1 were the most efficient in 3-ABA 318 
conversion. The results of this work also support our former findings showing a 319 
suitability of the rat as an appropriate animal model to study the fate of 3-ABA in 320 
humans (Arlt et al. 2004b; Stiborova et al. 2006a). Namely, here we have found that 321 
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human CYPs of a 3A subfamily (CYP3A and 3A5), orthologous CYPs to rat enzymes 322 
mentioned above, followed by human and rat CYP1A1, are the most efficient in 3-323 
ABA metabolism.  324 
In conclusion, the present study characterizing two metabolites formed from 3-325 
ABA by CYP-mediated oxidation, namely, a metabolite of 3-ABA, which is 326 
responsible for generation of 3-ABA-derived DNA adducts (N-hydroxy-3-ABA) and its 327 
final oxidation product (3-NBA), confirmed the participation of CYP1A enzymes in 328 
metabolic activation of 3-ABA (Arlt et al. 2004b). Other rat and human CYP enzymes, 329 
such a CYP3A and 2C are mainly important for detoxification metabolism of this 330 
compound. Structural characterization of the major detoxification metabolite of 3-ABA 331 
awaits further investigation. 332 
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Table 1. Kinetic parameters of 3-ABA oxidation catalyzed by hepatic microsomal 494 
CYPs 495 
 496 
 497 
Parameters 
Hepatic microsomes 
from rats pretreated with 
Km  
     Km1                     Km2 
[µM] 
Vmax 
     Vmax1                                      Vmax2  
[nmol 3-ABA min−1 mg−1]
 
β -naphtoflavone 
(CYP1A1/2) 
47.5 ± 0.5 13.42± 0.134 
Phenobarbital 
(CYP2B) 
60.7 ± 0.6 16.8 ± 0.168 
Control 20.7 ± 0.2        417.5 ± 4.18   3.4 ± 0,3                   48.5 ± 4.85 
 498 
Experimental conditions are described in Material and methods, 3-ABA (5 - 50 µM) 499 
and 0.5 mg microsomal protein were present in the incubation mixtures to determine 500 
the Km and Vmax values. Values in the table are averages and standard deviations of 501 
three determinations. 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
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Table 2. The effects of CYP inhibitors on 3-ABA oxidation by rat hepatic microsomes 520 
 521 
 522 
Hepatic microsomes from 
rats pretreated witha 
Inhibitorb IC50 [µM]c 
β-naphtoflavone 
(CYP1A1/2) 
α-naphtoflavone 
(CYP1A1/2) 10.9 ± 1.0 
β-naphtoflavone 
(CYP1A1/2) 
Furafylline 
(CYP1A2) 16.6 ± 1.6 
Untreated Sulfaphenazole 
(CYP2C) 
10.8 ± 1.0 
Untreated DDTC 
(CYP2E1) 96.8 ± 6.1 
Untreated Ketoconazole 
(CYP3A4) 3.5 ± 0.3 
 523 
aIsoforms of CYPs induced by inducers are shown in brackets. bIsoforms of CYP 524 
inhibited by selective inhibitors are shown in brackets. cEstimated from concentration-525 
dependent inhibition of 3-ABA oxidation by interpolation (inhibitors were 1 – 1000 µM 526 
depending on the chemical). 3-ABA (20 µM) and 0.5 mg microsomal protein were 527 
present in the incubation mixture. dAverages and standard deviations of three 528 
determinations.  529 
 530 
 531 
 532 
 533 
 534 
535 
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Figure 1. Pathways of metabolism and DNA adduct formation of 3-NBA and 3-ABA. 536 
See text for details. NQO1, NAD(P)H:quinone oxidoreductase; NAT, N,O-537 
acetyltransferases; SULT, sulfotransferase; PHS-1, prostaglandin H synthase-1 538 
(cyclooxygenase 1); CYP, cytochrome P450; LPO, lactoperoxidase; MPO, 539 
myeloperoxidase; POR, NADPH:cytochrome P450 oxidoreductase; R = -COCH3 or -540 
SO3H.   R = -COCH3 or -SO3H; dA-N6-ABA, 2-(2’-deoxyadenosin-N6-yl)-3-541 
aminobenzanthrone; dG-N2-ABA, N-(2’-deoxyguanosin-N2-yl)-3-aminobenzanthrone; 542 
dG-C8-N-ABA, N-(2’-deoxyguanosin-8-yl)-3-aminobenzanthrone. 543 
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Figure 2. HPLC chromatographs of 3-ABA metabolites produced by hepatic 558 
microsomes of rats treated with β-NF (A), HPLC profiles of several standards; 3-ABA 559 
(B), N-hydroxy-3-ABA (C) and 3-NBA (D). 560 
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Figure 3. Time dependence of 3-ABA oxidation by hepatic microsomes of rats treated 595 
with β-NF (A), PB (B), and by those of control (uninduced) rats (C). Experimental 596 
conditions are described in Material and methods. Values of reaction rates of 3-ABA 597 
oxidation are averages and standard deviations of triplicate incubation. MS; 598 
microsomes 599 
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Figure 4. Double reciprocal plots of initial velocities of 3-ABA oxidation versus 640 
concentrations of 3-ABA catalyzed  by hepatic microsomes of rats treated with PB 641 
(A), β-NF (B) and those of control (untreated) rats (C). Reaction rate (v) [nmol 3-642 
ABA/min/mg protein]. Experimental conditions are described in Material and 643 
methods.  644 
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Figure 5. Oxidation of 3-ABA by recombinant CYPs of rat (A) and human (B). 684 
Experimental conditions are described in Material and methods. Values of reaction 685 
rates of 3-ABA oxidation are averages and standard deviations of triplicate 686 
incubation. 687 
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